A new peer-reviewed study suggests semaglutide — the active ingredient in Ozempic and Wegovy — may do more than lower blood sugar and reduce body weight. A pilot analysis from the SLIM LIVER trial found the drug could influence epigenetic aging, a biological measure of how quickly cells are aging at the DNA level.
What the Study Looked At
The research is a post hoc analysis of the SLIM LIVER study (formally known as ACTG A5371, trial number NCT04216589, registered January 2, 2020). The 24-week, single-arm trial enrolled 41 people living with HIV (PWH) who also had metabolic dysfunction-associated steatotic liver disease (MASLD), a condition involving excess fat buildup in the liver tied to metabolic health problems. Participants received semaglutide 1.0 mg weekly and researchers then conducted this analysis to evaluate whether the drug affected epigenetic aging — biological clocks embedded in DNA that can differ from a person's calendar age — and whether those changes were linked to how well patients responded to treatment. The findings were published in the journal NPJ Aging.
Why Epigenetic Aging Matters
Epigenetic clocks measure chemical modifications on DNA that accumulate over time and are associated with biological aging. When these clocks run faster than expected for a person's actual age, it has been linked to higher risks of chronic disease and earlier death. Semaglutide is already known to improve metabolic health and reduce liver fat in people with conditions like MASLD. This study asked whether those metabolic benefits might extend to slowing biological aging at the cellular level — a meaningful question, particularly for people living with HIV, who often experience accelerated aging-related health challenges.
Key takeaway: This was a small, 41-person pilot study in a specific population — people with HIV and fatty liver disease. The results are preliminary and cannot yet be generalized to the broader population of people taking semaglutide for weight loss or diabetes.
What This Could Mean for Patients
If further research confirms these findings, it could add a new dimension to how GLP-1 receptor agonists like semaglutide are understood and prescribed. Most patients currently take Ozempic for type 2 diabetes management or Wegovy for chronic weight management — but interest in the drugs' broader effects on aging, inflammation, and organ health is growing rapidly in the scientific community. For now, this study does not change any prescribing guidelines or approved uses of semaglutide.
What to Watch Next
Because this was a pilot analysis with a small, specialized patient group, larger and more diverse clinical trials will be needed to determine whether semaglutide's potential effect on epigenetic aging holds up across different populations. Researchers and clinicians will be watching for follow-up studies that include people without HIV and that compare semaglutide directly against a placebo or other treatments.
Frequently Asked Questions
This research is at an early stage and should not change how you use your medication. If you have questions about semaglutide and what the emerging science may mean for your personal health, speak with your prescriber or a qualified healthcare professional.
- Peer-reviewed journal article, NPJ Aging, 'Pilot study of epigenetic aging and treatment response to semaglutide in the SLIM LIVER study,' date not specified in source material.